Rapid diagnosis and shorter regimen for multidrug-resistant tuberculosis: A priority to improve treatment outcome.

PubWeight™: 0.75^‹?›

🔗 View Article (PMID 28144051)

Published in Lung India on February 01, 2017

Authors

Rajendra Prasad¹, Nikhil Gupta², Amitabh Banka¹

Author Affiliations

1: Department of Pulmonary Medicine, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India E-mail: rprasadkgmc@gmail.com.
2: Department of Internal Medicine, Era's Lucknow Medical College and Hospital, Lucknow, Uttar Pradesh, India.

Articles cited by this ↗

Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med (2010) 5.01

Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients. PLoS Med (2012) 4.69

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis. Lancet (2015) 2.69

High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis (2015) 1.88

High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis (2014) 1.69

Multidrug and extensively drug-resistant tuberculosis management: Evidences and controversies. Lung India (2012) 0.94

Multidrug resistant tuberculosis: trends and control. Indian J Chest Dis Allied Sci (2015) 0.89

Articles by these authors ⇆

2025 too short time to eliminate tuberculosis from India. Lung India (2017) 0.75